Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNIFY: Zervimesine in Geographic Atrophy
NCT05893537Phase 2Terminated
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Jun 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zervimesine in geographic atrophy (GA), sponsored by Cognition Therapeutics, Inc.. Started Jun 2023; status: terminated.
02
Drugs
zervimesine
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT05893537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05893537.